Product
FRSW117
Aliases
PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection
3 clinical trials
1 indication
Indication
Hemophilia AClinical trial
Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Recombinant Human Coagulation Factor Ⅷ-Fc Fusion Protein (FRSW117) for Injection in Patients With Severe Hemophilia A (Adults and Adolescents)Status: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
An Open-Label, Multicenter Evaluation of the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in Patients With Severe Hemophilia A.Status: Completed, Estimated PCD: 2021-10-17
Clinical trial
A Phase II, Multicentre, Open-label Study to Evaluate the Pharmacokinetic, Safety and Preliminary Efficacy of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Subjects With Severe Hemophilia AStatus: Completed, Estimated PCD: 2022-08-21